This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Apollo Endosurgery Croissance future

Future contrôle des critères 2/6

Informations clés

n/a

Taux de croissance des bénéfices

n/a

Taux de croissance du BPA

Medical Equipment croissance des bénéfices	17.4%
Taux de croissance des recettes	32.1%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	05 Apr 2023

Mises à jour récentes de la croissance future

Recent updates

What Percentage Of Apollo Endosurgery, Inc. (NASDAQ:APEN) Shares Do Insiders Own?

Mar 03

Trade Alert: Neil Gagnon At Apollo Endosurgery, Inc. (NASDAQ:APEN), Has Just Spent US$146k Buying 2.8% More Shares

Feb 10

We Think Apollo Endosurgery (NASDAQ:APEN) Has A Fair Chunk Of Debt

Jan 31

Assessing Apollo Endosurgery

Dec 27

If You Had Bought Apollo Endosurgery's (NASDAQ:APEN) Shares Three Years Ago You Would Be Down 36%

Dec 27

Is It Too Late To Consider Buying Apollo Endosurgery, Inc. (NASDAQ:APEN)?

Dec 01

Apollo Endosurgery EPS beats by $0.10, beats on revenue

Nov 05

Prévisions de croissance des bénéfices et des revenus

NasdaqGM:APEN - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2025	181	N/A	-31	N/A	1
12/31/2024	117	N/A	-28	N/A	1
12/31/2023	89	-34	-30	N/A	2
12/31/2022	77	-40	-34	-31	N/A
9/30/2022	72	-41	-28	-25	N/A
6/30/2022	68	-36	-25	-23	N/A
3/31/2022	66	-28	-21	-19	N/A
12/31/2021	63	-25	-16	-14	N/A
9/30/2021	60	-18	-14	-13	N/A
6/30/2021	56	-14	-15	-14	N/A
3/31/2021	45	-17	-19	-19	N/A
12/31/2020	42	-23	-21	-21	N/A
9/30/2020	41	-26	-26	-25	N/A
6/30/2020	40	-32	-27	-26	N/A
3/31/2020	48	-35	-27	-26	N/A
12/31/2019	51	-27	-27	-26	N/A
9/30/2019	54	-39	-24	-23	N/A
6/30/2019	57	-40	-21	-20	N/A
3/31/2019	58	-40	-24	-22	N/A
12/31/2018	61	-46	-26	-23	N/A
9/30/2018	62	-35	-26	-23	N/A
6/30/2018	64	-30	-27	-24	N/A
3/31/2018	66	-27	-20	-17	N/A
12/31/2017	64	-27	-15	-13	N/A
9/30/2017	64	-33	-18	-16	N/A
6/30/2017	63	-36	-16	-14	N/A
3/31/2017	63	-41	-14	-12	N/A
12/31/2016	65	-41	-15	-13	N/A
9/30/2016	66	-36	N/A	-8	N/A
6/30/2016	66	-38	N/A	-7	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Insufficient data to determine if APEN's forecast earnings growth is above the savings rate (2.1%).

Bénéfices vs marché: Insufficient data to determine if APEN's earnings are forecast to grow faster than the US market

Croissance élevée des bénéfices: Insufficient data to determine if APEN's earnings are expected to grow significantly over the next 3 years.

Chiffre d'affaires vs marché: APEN's revenue (32.1% per year) is forecast to grow faster than the US market (6.9% per year).

Croissance élevée des revenus: APEN's revenue (32.1% per year) is forecast to grow faster than 20% per year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Insufficient data to determine if APEN's Return on Equity is forecast to be high in 3 years time

This company has been acquired

Apollo Endosurgery Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased to US$11.75

Apollo Endosurgery, Inc. Raises Revenue Guidance for the Fiscal Year 2022

Consensus forecasts updated

Apollo Endosurgery, Inc. Reiterates Revenue Guidance for the Fiscal Year 2022

Consensus forecasts updated

Price target decreased to US$12.67

Recent updates

Is Apollo Endosurgery (NASDAQ:APEN) Using Debt Sensibly?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Boston Scientific Corporation (NYSE:BSX) entered into a definitive merger agreement to acquire Apollo Endosurgery, Inc. (NasdaqGM:APEN) for approximately $440 million.

Price target decreased to US$11.75

Boston Scientific Corporation (NYSE:BSX) entered into a definitive merger agreement to acquire Apollo Endosurgery, Inc. (NasdaqGM:APEN) for approximately $440 million.

Is Apollo Endosurgery (NASDAQ:APEN) Weighed On By Its Debt Load?

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Apollo Endosurgery, Inc. Raises Revenue Guidance for the Fiscal Year 2022

Apollo Endosurgery, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Consensus forecasts updated

Is Apollo Endosurgery (NASDAQ:APEN) Using Too Much Debt?

Apollo Endosurgery: Collect Shares At A Discount Following Q2 Earnings

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Apollo Endosurgery, Inc. Reiterates Revenue Guidance for the Fiscal Year 2022

Apollo Endosurgery, Inc. to Report Q2, 2022 Results on Aug 02, 2022

FDA Grants De Novo Marketing Authorization to Apollo Endosurgery for Apollo ESG(TM) and Apollo REVISE(TM), New Endoscopic Systems for Patients with Obesity

Apollo Endosurgery, Inc. Announces Executive Changes

Apollo Endosurgery, Inc.(NasdaqGM:APEN) dropped from Russell Microcap Value Index

Apollo Endosurgery, Inc., Annual General Meeting, Jun 14, 2022

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Apollo Endosurgery, Inc. to Report Q1, 2022 Results on May 03, 2022

Apollo Endosurgery, Inc. Appoints Jeannette Bankes to Board of Directors

CFO, Secretary & Treasurer recently bought US$229k worth of stock

Is Apollo Endosurgery (NASDAQ:APEN) Using Debt Sensibly?

Full year 2021 earnings: EPS exceeds analyst expectations

Consensus forecasts updated

Apollo Endosurgery, Inc. Announces Board Changes

Price target decreased to US$12.67

Apollo Endosurgery, Inc. Provides Preliminary, Un-Audited Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021

Third quarter 2021 earnings released: US$0.23 loss per share (vs US$0.11 loss in 3Q 2020)

CEO, President & Director recently sold US$504k worth of stock

CEO, President & Director recently sold US$504k worth of stock

Chief Financial Officer recently bought US$219k worth of stock

Consensus forecasts updated

Price target increased to US$14.00

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.30 loss in 2Q 2020)

Is Apollo Endosurgery, Inc. (NASDAQ:APEN) Trading At A 20% Discount?

Apollo Endosurgery: New Management Bounce Makes Weight Loss Specialist A Buy

Insider recently sold US$129k worth of stock

Price target increased to US$11.25

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.49 loss in 1Q 2020)

Is Apollo Endosurgery (NASDAQ:APEN) A Risky Investment?

Apollo Endosurgery EPS beats by $0.05, beats on revenue

A Look At The Intrinsic Value Of Apollo Endosurgery, Inc. (NASDAQ:APEN)

Independent Chairman of the Board recently bought US$59k worth of stock

Apollo Endosurgery, Inc. Announces Departure of Todd Newton as Chief Executive Officer

What Percentage Of Apollo Endosurgery, Inc. (NASDAQ:APEN) Shares Do Insiders Own?

New 90-day high: US$6.10

Full year 2020 earnings released: US$0.99 loss per share (vs US$1.27 loss in FY 2019)

Insider recently bought US$86k worth of stock

Revenue beats expectations, earnings disappoint

Apollo Endosurgery, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Insider recently bought US$146k worth of stock

Trade Alert: Neil Gagnon At Apollo Endosurgery, Inc. (NASDAQ:APEN), Has Just Spent US$146k Buying 2.8% More Shares

Apollo Endosurgery, Inc. Announces Management Changes, Effective as of March 1, 2021

New 90-day high: US$4.86

We Think Apollo Endosurgery (NASDAQ:APEN) Has A Fair Chunk Of Debt

Assessing Apollo Endosurgery

If You Had Bought Apollo Endosurgery's (NASDAQ:APEN) Shares Three Years Ago You Would Be Down 36%

Is It Too Late To Consider Buying Apollo Endosurgery, Inc. (NASDAQ:APEN)?

New 90-day high: US$2.30

Analysts increase revenue estimates to US$40.2m

Third quarter 2020 earnings released: US$0.11 loss per share

Revenue beats expectations, earnings disappoint

Apollo Endosurgery EPS beats by $0.10, beats on revenue

New 90-day high: US$1.79

New 90-day low - US$1.31

First half earnings released